Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

Annals of Hematology

Volumn 94, Issue 4, 2015, Pages 565-573

  Font, Patricia ^a,b   Loscertales, Javier ^c   Soto, Carlos ^d   Ricard, Pilar ^e   Novas, Carolina Muñoz ^f   Martín Clavero, Estela ^g   López Rubio, Montserrat ^h   Garcia Alonso, Luis ⁱ   Callejas, Marta ^h   Bermejo, Alfredo ^j   Benavente, Celina ^k   Ballesteros, Mónica ^a   Cedena, Teresa ^g   Calbacho, María ^l   Urbina, Raquel ^a   Villarrubia, Jesús ^l   Gil, Santiago ^m   Bellón, José María ^b   Diez Martin, José Luis ^a,b   Villegas, Ana ^k  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^f HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^j HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL RAMÓN Y CAJAL   (Spain)

^m HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

Myelodysplastic syndromes (MDS); R IPSS; RARS; RCUD; WHO classification

Indexed keywords

HEMOGLOBIN;

5Q- SYNDROME; ARTICLE; BLAST CELL; CELL COUNT; CYTOGENETICS; CYTOPENIA; DISEASE CLASSIFICATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PANCYTOPENIA; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; RELIABILITY; REPRODUCIBILITY; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNCLASSIFIABLE MYELODYSPLASTIC SYNDROME; WORLD HEALTH ORGANIZATION; BLAST CELL CRISIS; BONE MARROW; CELL LINEAGE; CYTODIAGNOSIS; MYELODYSPLASTIC SYNDROMES; OBSERVER VARIATION; PATHOLOGY; STATISTICS AND NUMERICAL DATA;

BLAST CRISIS; BONE MARROW; CELL COUNT; CELL LINEAGE; CYTODIAGNOSIS; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84925501247     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2252-4     Document Type: Article

References (29)

1. Garcia-Manero G (2014) Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:98–108
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) French–American–British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199
3. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 63–67
4. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93
5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088
6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510
7. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829
8. Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465
9. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z et al (2011) Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118:4690–4693
10. Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L (2013) Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 98:568–575
11. Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L et al (2013) Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 92:19–24
12. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
13. Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Spanish Myelodysplastic Syndrome Registry et al (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 117:5529–5537
14. Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B et al (2013) Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res 37:64–70
15. Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C (2000) Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 108:724–728
16. Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992
17. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604
18. Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T (2012) Prognosis of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 36:826–831
19. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506
20. Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N et al (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376–3382
21. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al (2011) Somatic SF3B1 mutation in myelodysplasia with ringed sideroblasts. N Engl J Med 365:1384–1395
22. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69
23. Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al (2012) Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 119:5674–5677
24. Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al (2013) Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27:1826–1831
25. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda S et al (1998) Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12:482–485
26. Germing U, Kuendgen A (2012) Prognostic scoring systems in MDS. Leuk Res 36:1463–1469
27. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et al (2008) International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717
28. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270
29. Van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS et al (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 54:472–475